Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014) | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in <scp>DAYBREAK</scp> Trial ParticipantsHuman Clinical Trial · 2026
2Updated Study Data for Ozanimod in Relapsing Multiple Sclerosis2024
3Safety Patterns over Time with Ozanimod During an Open-label Extension Trial in Patients with Relapsing Multiple Sclerosis (P10-6.012)2024 · 1 citations
4Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod (P6-6.006)2024
5Real-world Experience With Ozanimod at Two Academic Multiple Sclerosis Centers With Expanded 24-month Data (P4-20.003)Original Research · 2026
6Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials and an Open-label Extension Trial (P2-6.007)2024
7Relapse‐Associated and Relapse‐Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Erascohort · 2024 · 14 citations
8Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study (P10-6.014)2024
9A Review of the Association Between Pulse Wave Velocity and Cerebral Small Vessel Disease (P1-4.009)Neurology · 2026
10Factors Associated With Rate of Multiple Sclerosis Onset in a Cohort With Prior Infectious Mononucleosis Identified in Administrative DataNeurology · 2026

More from Neurology

More from Harvard University